No statistically significant change in MADRS total score was observed with solriamfetol vs placebo in the overall study population. Topline results were announced from a phase 3 trial evaluating ...

NEW YORK, April 01, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today ...

D-serine as an adjunctive treatment did not outperform placebo overall in patients with major depressive disorder (MDD), a new trial showed. However, depressive symptoms and anhedonia were ...

Observing behavior in a simple video game may help identify major depressive disorder and depression severity.

The use of 42 mg lumateperone combined with antidepressant therapy was linked to significantly reduced severity of depression and anxiety, as well as greater response and remission rates, and was ...

Researchers found that 8.3% of US adults had at least one major depressive episode. In adolescents, the rate was 20.1%, with 29.2% of female adolescents reporting a major depressive episode. Major ...

A controlled clinical trial suggests a fast-acting psychedelic approach may reduce depressive symptoms, but researchers stress careful interpretation and the need for larger long-term studies. Study: ...